Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,824 across all filing types
Latest filing 2024-04-10 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
哈药集团股份有限公司董事会关于独立董事独立性情况的专项意见
Board/Management Information Classification · 95% confidence The document is a special opinion from the board of directors regarding the independence of the company's independent directors, referencing regulatory requirements from the China Securities Regulatory Commission and the Shanghai Stock Exchange. It evaluates the independence of specific directors and confirms compliance with relevant rules. This type of document is related to board or management information about governance and director status, not a full report or announcement of voting results. It is not a financial report, earnings release, or regulatory filing in the general sense. Therefore, the best fitting category is Board/Management Information (MANG). The document is short and focused on management-level information about directors' independence.
2024-04-10 Chinese
哈药集团股份有限公司关于购买董监高责任险的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the purchase of directors and officers liability insurance by the company. It includes details about the insurance plan, the decision-making process by the board and supervisory committee, and the submission of the proposal to the shareholders' meeting for approval. The document is a formal announcement of a corporate governance-related matter, specifically about risk management and insurance for directors and officers. It does not contain financial statements, audit results, or detailed financial data. It is not a report itself but an announcement of a corporate action related to governance and risk management. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-04-10 Chinese
哈药集团股份有限公司关于修改《公司章程》的公告
Governance Information Classification · 95% confidence The document is an announcement from 哈药集团股份有限公司 regarding amendments to the company's Articles of Association (公司章程). It details changes in registered capital and revisions to specific articles of the Articles of Association. The document is a formal announcement of these changes and states that the amendments require shareholder approval at a general meeting. The document length is short (1264 characters), and it does not contain financial statements or detailed financial data. It is not a full report but an announcement of corporate governance changes related to the company's charter. Therefore, it fits best under the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2024-04-10 Chinese
哈药集团股份有限公司十届二次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 10th Board of Directors' second meeting of Harbin Pharmaceutical Group Co., Ltd. It includes approval of the 2023 Annual Report, financial results, profit distribution plan, asset impairment provisions, internal control reports, auditor changes, and various governance and operational matters. The document references the 2023 Annual Report and other reports being disclosed on the Shanghai Stock Exchange website but does not contain the full annual report itself. The document is a formal board meeting resolution announcement with voting results and summaries of key financial and governance decisions. It is not the full Annual Report (10-K), nor is it a simple announcement of report publication (RPA) because it contains substantive board decisions and voting outcomes. It is not a Management Report (MDA) or Earnings Release (ER) as it covers a broad range of board resolutions beyond financial results. The document is best classified as Board/Management Information (MANG) because it reports on board meeting decisions, including approval of reports, financial budgets, auditor appointments, and governance changes.
2024-04-10 Chinese
哈药集团股份有限公司关于变更会计师事务所的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the change of the company's accounting firm for auditing services. It details the new and previous accounting firms, reasons for the change, the selection process, and approvals by the audit committee and board of directors. It does not contain any financial statements, audit reports, or detailed financial data itself, but rather informs about the appointment of a new auditor. The document length is 3102 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about auditor change and does not qualify as an Audit Report (AR) or Annual Report (10-K).
2024-04-10 Chinese
哈药集团股份有限公司总裁工作细则（2024年4月）
Governance Information Classification · 95% confidence The document is titled '总裁工作细则' (President Work Rules) for 哈药集团股份有限公司 and details the duties, qualifications, appointment procedures, and reporting obligations of the company's president and senior management. It references company governance, internal management rules, and compliance with laws and regulations. There are no financial statements, earnings data, or audit information. The document is a governance-related internal policy document rather than a financial report or announcement. It is not a report publication announcement or a certification. Therefore, it fits best under Governance Information (CGR), which covers internal rules and governance practices.
2024-04-10 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.